Table 1.

Clinical results with combinations of programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors and platinum-based chemotherapy regimens as first-line therapy for metastatic non-small cell lung cancer (NSCLC)

Clinical study	Investigational agent and subgroup	Progression-free survival		Response rate		Median overall survival		Reference
KEYNOTE-189 (n = 616) Cisplatin/carboplatin + pemetrexed ± pembrolizumab	Pembrolizumab Non-squamous NSCLC No EGFR/ALK/ROS-1 mutation	Active	Control	Active	Control	Active	Control
		8.8 months 35% alive and progression free at 12 months	4.9 months 18% alive and progression free at 12 months	48%	19%	NR	11.3 months	[4]
KEYNOTE-407 (n = 559) Carboplatin + nab paclitaxel/paclitaxel ± pembrolizumab	Pembrolizumab Squamous NSCLC No EGFR/ALK/ROS-1 mutation	6.4 months 31% alive and progression free at 12 months	4.8 months 15% alive and progression free at 12 months	57%	36%	15.9 months	11.3 months	[5]
Impower150 (Arm B versus C; n = 800) Carboplatin + paclitaxel + bevacizumab ± atezolizumab	Atezolizumab Non-squamous NSCLC No EGFR/ALK/ROS-1 mutation	8.4 months 38% alive and progression free at 12 months	6.8 months 20% alive and progression free at 12 months	56%	40%	19.2 months	14.7 months	[6]
Impower 131 (Arm B versus C; n = 688) Carboplatin + paclitaxel + bevacizumab ± atezolizumab	Atezolizumab Squamous NSCLC No EGFR/ALK/ROS-1 mutation	6.3 months 25% alive and progression free at 12 months	5.6 months 12% alive and progression free at 12 months	49%	41%	14 months	13.9 months	[7]